Free public records show Acs Dobfar SpA in 4 of the markets we cover. It is not a key player in our research.
From public registers, not from Acuitas research, with a citation under every number. Each card opens the full list at its source.
26 approvals with a product on the US market
Source: Drugs@FDA, Approvals (NDA, ANDA, BLA) held, with a product sold now; newest shown. Retrieved 13 Nov 2026.
Markets we cover where free public records show Acs Dobfar SpA: trials they lead, US approvals or WHO prequalification. Each opens the market's report, with the record counts and their sources.
The topics of the markets Acs Dobfar SpA is in.
Stories on the topics Acs Dobfar SpA works in.
Nearly 15% of US Medicare beneficiaries, 8.2 million people, had a wound or wound infection in one year…
Read
TB killed 1.23 million people in 2024. WHO now recommends rapid molecular tests first, bringing lab-grade…
Read
Drug-resistant infections already kill over a million people a year. Faster testing helps doctors pick the…
Read